American Assets Investment Management LLC maintained its stake in GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 30,000 shares of the pharmaceutical company’s stock at the end of the second quarter. American Assets Investment Management LLC’s holdings in GlaxoSmithKline PLC were worth $1,294,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of GSK. Bank of Montreal Can increased its stake in GlaxoSmithKline PLC by 8.8% in the first quarter. Bank of Montreal Can now owns 128,238 shares of the pharmaceutical company’s stock worth $5,407,000 after buying an additional 10,412 shares in the last quarter. Regentatlantic Capital LLC acquired a new stake in GlaxoSmithKline PLC during the first quarter worth approximately $268,000. Fox Run Management L.L.C. acquired a new stake in GlaxoSmithKline PLC during the first quarter worth approximately $649,000. Howland Capital Management LLC increased its stake in GlaxoSmithKline PLC by 8.6% in the first quarter. Howland Capital Management LLC now owns 6,853 shares of the pharmaceutical company’s stock worth $289,000 after buying an additional 545 shares in the last quarter. Finally, Private Wealth Partners LLC increased its stake in GlaxoSmithKline PLC by 34.6% in the first quarter. Private Wealth Partners LLC now owns 12,000 shares of the pharmaceutical company’s stock worth $506,000 after buying an additional 3,083 shares in the last quarter. Institutional investors own 8.99% of the company’s stock.

GlaxoSmithKline PLC (GSK) opened at 39.24 on Thursday. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.58. The firm has a market capitalization of $95.90 billion, a PE ratio of 37.95 and a beta of 1.03. The company’s 50-day moving average price is $41.41 and its 200 day moving average price is $41.86.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The company had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. On average, equities analysts anticipate that GlaxoSmithKline PLC will post $2.85 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be given a $0.491 dividend. The ex-dividend date of this dividend is Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a yield of 5.01%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 197.00%.

TRADEMARK VIOLATION NOTICE: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/17/american-assets-investment-management-llc-has-1294000-position-in-glaxosmithkline-plc-gsk.html.

A number of equities research analysts have commented on GSK shares. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday, April 25th. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, April 25th. TheStreet upgraded GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research report on Friday, May 19th. Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. Finally, ValuEngine downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the stock. GlaxoSmithKline PLC has a consensus rating of “Hold” and a consensus price target of $44.67.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.